Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis

被引：0
|
作者：
Neide Tomimura Costa
Tatiana Mayumi Veiga Iriyoda
Daniela Frizon Alfieri
Andréa Name Colado Simão
Isaias Dichi
机构：
[1] University of Londrina,Department of Rheumatology
[2] Pontifícia Universidade Católica (PUC),Department of Rheumatology
[3] University of Londrina,Research Laboratory of Applied Immunology
[4] University of Londrina,Department of Pathology, Clinical Analysis and Toxicology
[5] University of Londrina,Department of Internal Medicine
来源：
Inflammopharmacology | 2018年 / 26卷
关键词：
Disease-modifying antirheumatic drugs; Rheumatoid arthritis; Oxidative stress; Nitrosative stress;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1151 / 1164
页数：13
相关论文
共 50 条
  • [41] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    [J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655
  • [42] SAFETY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN JUVENILE RHEUMATOID-ARTHRITIS (JRA)
    KVIEN, TK
    HOYERAAL, HM
    SANDSTAD, B
    KASS, E
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1984, : 112 - 112
  • [43] Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis
    Feely, Michael G.
    O'Dell, James R.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (03) : 316 - 320
  • [44] Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
    Kremer, J
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (05): : 636 - 638
  • [45] Pharmacoepidemiological analysis of disease-modifying antirheumatic drugs adverse effects in rheumatoid arthritis
    Reshetko, O.
    Levitan, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S33 - S33
  • [46] Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis
    Yamanaka, Hisashi
    Kishimoto, Mitsumasa
    Nishijima, Nobuo
    Yamashita, Katsuhisa
    Matsushima, Junnosuke
    O'Brien, Jacqueline
    Blachley, Taylor
    Eliot, Melissa
    Margolin, Zachary
    Dave, Swapna S.
    Tanaka, Yoshiya
    [J]. MODERN RHEUMATOLOGY, 2023, 34 (01) : 27 - 36
  • [47] Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Inose, Ryo
    Hashimoto, Natsue
    Hosomi, Kouichi
    Yokoyama, Satoshi
    Takada, Mitsutaka
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (03) : 131 - 138
  • [48] PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Schlager, Lukas
    Loiskandl, Michaela
    Aletaha, Daniel
    Radner, Helga
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1152 - 1153
  • [49] Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella, AC
    O'Dell, JR
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (03) : 185 - 192
  • [50] Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine
    Mirkov, Masa Umicevic
    Coenen, Marieke J. H.
    [J]. PHARMACOGENOMICS, 2013, 14 (04) : 425 - 444
12345